Replies to post #813 on Fate Therapeutics Inc (FATE)

[NY1972]

CD19 TCE only viable target
Every teclistamab pt. received IVIG. $CGEM BCMA TCE, CART are DOA
Monthly cost: Some patients may need IVIG monthly, which can result in costs exceeding $40,000 a month before insurance.
https://acrabstracts.org/abstract/safety-and-efficacy-of-t-cell-engager-therapy-in-patients-with-refractory-autoimmune-disease/

[NY1972]

another frontier, inflammatory diseases

CD19 CAR-T coming to IBD $CABA $KYTX $CGEM

New N=1 case report from Schett describes clinical / biochemical remission achieved with auto CD19 CAr-T in refractory Ulcerative Colitis

Can't find the article anywhere... potentially a bungled embargo? Should be on NEJM soon enough pic.twitter.com/I1ckADrduu

— Professor Oak (@Prof_Oak_) September 23, 2025

[jondoeuk]

PR https://www.globenewswire.com/news-release/2025/10/26/3174247/24675/en/Fate-Therapeutics-Presents-New-Clinical-Data-at-ACR-Convergence-2025-Demonstrating-Immune-Remodeling-and-Durable-Responses-in-Patients-with-Systemic-Lupus-Erythematosus-Treated-wit.html

Poster https://www.fatetherapeutics.com/wp-content/uploads/2025/10/ACR-2025_Poster-0663_Fazeli-et-al.pdf